Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX-Based Total Neoadjuvant Therapy in Locally Advanced Pancreatic Cancer
ChiCTR2600119985Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of NALIRIFOX in pancreatic adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Intention-to-treat (ITT) R0 resection rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
NALIRIFOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600119985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119985.